$189 Million is the total value of Soleus Capital Management, L.P.'s 63 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ITMR | ITAMAR MED LTDsponsored ads | $2,871,000 | +9.9% | 140,524 | 0.0% | 1.52% | +2.1% | |
| RFL | RAFAEL HLDGS INC | $1,623,000 | +7.8% | 104,737 | 0.0% | 0.86% | +0.2% | |
| GOSSAMER BIO INCnote 5.000% 6/0 | $1,021,000 | +2.0% | 1,000,000 | 0.0% | 0.54% | -5.3% | ||
| KDMN | KADMON HLDGS INC | $787,000 | -23.4% | 200,841 | 0.0% | 0.42% | -28.8% | |
| ENTA | ENANTA PHARMACEUTICALS INC | $526,000 | -8.8% | 11,500 | 0.0% | 0.28% | -15.2% | |
| INSMED INCnote 1.750% 1/1 | $195,000 | +12.1% | 180,000 | 0.0% | 0.10% | +4.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ESSA PHARMA INC | 16 | Q3 2023 | 10.8% |
| IRADIMED CORP | 16 | Q3 2023 | 5.8% |
| XENON PHARMACEUTICALS INC | 15 | Q3 2023 | 2.9% |
| IVERIC BIO INC | 14 | Q1 2023 | 6.5% |
| SURMODICS INC | 14 | Q3 2023 | 4.7% |
| NATERA INC | 13 | Q3 2023 | 3.9% |
| DEXCOM INC | 13 | Q2 2023 | 4.2% |
| NOVOCURE LTD | 13 | Q3 2023 | 3.4% |
| CRISPR THERAPEUTICS AG | 13 | Q2 2023 | 2.6% |
| LYRA THERAPEUTICS INC | 13 | Q3 2023 | 1.0% |
View Soleus Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Soleus Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.